Cases & Deals

Celgene establishes global patent portfolio for its brands REVLIMID®, POMALYST®, OTEZLA®, VIDAZA®, ABRAXANE® and ISTODAX®

Clients Celgene Corporation

Jones Day assists Celgene Corporation in the establishment of its global patent portfolio related to lenalidomide (REVLIMID®), pomalidomide (POMALYST®), apremilast (OTEZLA®), azacitidine (VIDAZA®), ABRAXANE® and romidepsin (ISTODAX®) for the treatments of cancer and immune, inflammatory conditions.